Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Moderna, Inc. - Common Stock
(NQ:
MRNA
)
45.97
+2.04 (+4.63%)
Streaming Delayed Price
Updated: 1:35 PM EST, Feb 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Moderna, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Why Moderna Stock Just Popped
↗
Today 13:35 EST
So the FDA will consider Moderna's flu vaccine application after all. Does this make Moderna stock a buy?
Via
The Motley Fool
Wednesday's session: gap up and gap down stock in the S&P500 index
↗
Today 10:35 EST
Via
Chartmill
Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review
↗
Today 9:57 EST
The FDA has now accepted the biologics license application for review, setting a Prescription Drug User Fee Act goal date of Aug. 5, 2026.
Via
Stocktwits
What's going on in today's pre-market session: S&P500 movers
↗
Today 8:35 EST
Via
Chartmill
Moderna Inc (NASDAQ:MRNA) Beats Q4 2025 Estimates Amid Post-Pandemic Transition
↗
February 13, 2026
Via
Chartmill
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
Today 7:00 EST
Via
ACCESS Newswire
3 Stocks Under $50 with Warning Signs
February 17, 2026
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...
Via
StockStory
The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
February 17, 2026
As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Initial Public Offering
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
February 17, 2026
As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based...
Via
Finterra
Topics
Economy
Intellectual Property
Shopify's Whiplash Day
↗
February 17, 2026
It looked like Shopify's stock was headed for a great day when it reported earnings, only for the stock to give up all its gains and then some when management started talking on the conference call.
Via
The Motley Fool
Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
February 17, 2026
Via
ACCESS Newswire
3 Cash-Burning Stocks That Fall Short
February 15, 2026
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even...
Via
StockStory
Topics
Bankruptcy
MRNA Q4 Deep Dive: New Vaccines, Cost Controls, and Pipeline Milestones Shape Outlook
February 14, 2026
Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q4 CY2025, but sales fell by 29.8% year on year to $678 million. Its non-GAAP loss of $2.11 per share was 20.2%...
Via
StockStory
Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results
February 13, 2026
Moderna Inc. (NASDAQ: MRNA) shares jumped 8% in early trading on February 13, 2026, after the biotechnology pioneer reported fourth-quarter 2025 financial results that exceeded Wall Street’s...
Via
MarketMinute
Topics
Earnings
Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know
February 13, 2026
A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a...
Via
StockStory
Topics
Economy
Top S&P500 movers in Friday's session
↗
February 13, 2026
Via
Chartmill
Friday's session: top gainers and losers in the S&P500 index
↗
February 13, 2026
Via
Chartmill
Moderna (MRNA) Q4 2025 Earnings Call Transcript
↗
February 13, 2026
Moderna (MRNA) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Moderna (NASDAQ:MRNA) Exceeds Q4 CY2025 Expectations
February 13, 2026
Biotechnology company Moderna (NASDAQ:MRNA) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 29.8% year on year to $678 million. Its GAAP loss of $2.11 per share was 18.9% above...
Via
StockStory
Topics
Artificial Intelligence
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
February 13, 2026
Via
ACCESS Newswire
Nasdaq, S&P 500 Futures Edge Lower Ahead Of CPI Data: Why NVDA, AAPL, TSLA, RIVN, MRNA, AMAT, IREN Are On Traders' Radar Today
↗
February 13, 2026
Data on Stocktwits showed retail traders remained bearish on SPY and ‘extremely bearish’ on QQQ.
Via
Stocktwits
Topics
Bonds
ETFs
Economy
Moderna: Stock to Avoid or Bad News Buy?
↗
February 12, 2026
Moderna stock was a highflier in early pandemic days as sales of its coronavirus vaccine soared.
Via
The Motley Fool
FDA Stuns Moderna with Refusal to Review Flu Vaccine, Sending Shares Tumbling 3.5%
February 12, 2026
Shares of Moderna, Inc. (NASDAQ: MRNA) fell 3.5% on February 12, 2026, as investors continued to digest the fallout from a rare and unexpected regulatory setback. The U.S. Food and Drug Administration...
Via
MarketMinute
Topics
Earnings
The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation
February 12, 2026
The following research article examines NovoCure Limited (NASDAQ: NVCR) through a deep-dive lens, focusing on its pioneering role in bioelectronic oncology and its current strategic pivot as of...
Via
Finterra
Topics
Initial Public Offering
Intellectual Property
AI Agents and the Jobs Report Jitter: A Wall Street Balancing Act
↗
February 12, 2026
Via
Chartmill
Topics
Artificial Intelligence
What To Expect From Moderna’s (MRNA) Q4 Earnings
February 11, 2026
Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Friday before market hours. Here’s what to look for.
Via
StockStory
Topics
Artificial Intelligence
Exploring the top movers within the S&P500 index during today's session.
↗
February 11, 2026
Via
Chartmill
Gapping S&P500 stocks in Wednesday's session
↗
February 11, 2026
Via
Chartmill
Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology
February 11, 2026
Today, February 11, 2026, marks a volatile chapter for Moderna, Inc. (NASDAQ: MRNA). The biotechnology pioneer, which became a household name during the COVID-19 pandemic, finds itself at a critical...
Via
Finterra
Topics
Artificial Intelligence
Initial Public Offering
Intellectual Property
These S&P500 stocks are moving in today's pre-market session
↗
February 11, 2026
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.